Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Frontiers in Oncology- Switzerland

doi 10.3389/fonc.2019.00767

Full Text

Abstract

Available in

Date

Authors

Publisher

Frontiers Media SA


Related search